Introduction
Despite significant advances in health care, the mortality rate for end-stage renal disease (ESRD) patients remains unacceptably high [1] . Cardiovascular disease remains the number one cause of death among ESRD patients, followed by infectious diseases [1] . Known risk factors for mortality in ESRD patients include advanced age, history of diabetes mellitus, cardiovascular disease, cerebrovascular disease, neoplasms, autoimmune diseases and pulmonary disease [1] .
Much recent attention has focused on the role of increased inflammation in promoting progression of underlying comorbid illnesses, thus leading to increased mortality among ESRD patients. Several studies have shown an association between inflammatory markers and survival on dialysis [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . There is concern that, by reactivation of the inflammatory cascade [14] [15] [16] , the dialysis procedure may increase mortality.
We have previously shown that higher levels of pro-inflammatory circulating cytokines, in a cohort of 231 haemodialysis (HD) patients, were associated with increased mortality [12] . In addition, we showed that another set of markers, associated primarily with T-cell function, was associated with survival in this same cohort of patients [12] . Other studies have previously shown in univariate analyses that specific pro-inflammatory cytokines are individually associated with mortality [6, 17, 18] . Patterns of cytokine levels in individual ESRD patients who are stable on dialysis have not been evaluated often, in part because very few investigators have assessed a panel of cytokines. The underlying presumption has been that increased levels of pro-inflammatory cytokines are counterbalanced by high levels of anti-inflammatory cytokines as part of a regulatory system. However, this hypothesis has not been confirmed in a factor analysis of cytokine levels in ESRD patients. If various cytokine levels all load onto one factor, this would support the notion that patients with high pro-inflammatory cytokines should have high anti-inflammatory cytokine levels. Therefore, patients who have high levels of pro-inflammatory cytokines and low levels of anti-inflammatory cytokines or high levels of anti-inflammatory cytokines and low pro-inflammatory cytokines would seem to have relative dysregulation of the immune system.
The purpose of this study was to perform a factor analysis on the cytokine values from the cohort of 231 patients to determine whether these disparate individual cytokines load onto one or two discrete factors. A factor analytic approach could lead to greater clarity regarding the mechanism through which differential expression of cytokines among ESRD patients affects mortality. It is possible that a panel of cytokine parameters can characterize the inflammatory state of dialysis patients, as well as the anti-inflammatory component, and that more precise tools could be developed to assess patients' survival probability. A second objective of the study was to demonstrate that patterns of cytokine dysregulation at the extremes are associated with differential survival.
Our hypothesis was that several of the inflammatory cytokines previously associated with increased mortality would all load onto one discrete factor. In addition, we hypothesized that at least several of the T-cell functional cytokines previously associated with improved dialysis patient survival would all load onto another discrete factor. Our second hypothesis was that the group of patients with a pattern of high pro-inflammatory cytokines would have decreased survival compared to the rest of the cohort.
Materials and methods
A prospective observational study was performed using a database of 231 haemodialysis patients from which cytokine values were previously collected. The data were previously used in prospective studies of haemodialysis patients from three dialysis units in Washington, DC to study the relationship between immunologic function of ESRD patients and medical outcomes [12] . Cytokine levels were assessed from blood drawn from the patients at the time of their monthly laboratory evaluation.
Immunologic variables studied were total complement activity (CH50), interleukin-1 (IL-1), IL-2, IL-4, IL-5, IL-6, IL-12 and T-cell number. As previously described [12] , blood samples were obtained from patients before the start of a haemodialysis session. Circulating cytokine and TNF-α concentrations were measured by a chemiluminescence-enhanced capture enzyme-linked immunoabsorbent assay method [12] , using specific antibodies directed against each cytokine (R&D Systems, Minneapolis, MN, and Bachem Biosciences, King of Prussia, PA). Intra-assay and inter-assay coefficients of variation ranged between 2.18% and 4.59% [12] . Because the distribution of all these variables was skewed in the dialysis patients, a logarithmic transformation was performed on the cytokine values which created normalized distributions. We previously compared cytokine levels of the HD patients to 28 patients without renal disease [12] .
An exploratory factor and correlational analysis of the database using SAS version 8.2 was performed. A cutoff value of 0.3 was used to determine if a particular cytokine loaded onto factor 1 or 2. We also performed a frequency analysis to determine if there were particular common patterns of cytokine levels that characterized our cohort of 231 HD patients.
The median values of each cytokine were used to categorize each cytokine level as 'high' or 'low.' A high cytokine level was labeled as a value greater than the median for that particular cytokine. A low cytokine level was labeled as a value less than the median for that particular cytokine. We then determined if the patients could be stratified into common patterns of high or low cytokine levels. We performed a Kaplan-Meier survival analysis to determine if there was a significant difference in mortality between the pro-inflammatory group pattern compared to the anti-inflammatory and other group patterns. A Cox regression analysis was also performed using the three groups and with the following covariates and strata: age, albumin, ESRD severity coefficient index and dialysis site. All analyses were conducted using SAS version 8.2.
The ESRD severity coefficient has previously been validated [12, 19] in patients with ESRD and evaluates disease severity using the product of age and the relative mortality risk of comorbid conditions such as diabetes mellitus, cardiovascular and cerebrovascular disease, collagen vascular disease, malignancy and the type of renal disease [12] .
We evaluated the differences between groups using analysis of variance (ANOVA). P<0.05 was considered statistically significant. Results are expressed as the median and mean±SD.
All data were kept confidential, and all personal identifiable information was encrypted and not shared by members outside the investigational team. All data were collected before 1997. Participants in the study gave informed consent for the use of their data in mortality studies. The George Washington University Committee on Human Research approved this study. Table 1 summarizes the baseline demographic data of the patients. The cohort was made up of 231 patients with a recruitment rate of 56.8% of eligible subjects. Ninety-three percent of the patients were African-American, consistent with the demographics of dialysis units in Washington, DC. Of the patients, 30.9% were female, and 57.8% had diabetes mellitus. The mean patient age was 54.4±14.2 years. The patients had been treated for ESRD for a mean of 33.7±47.3 months. The mean Kt/V was 1.2±0.3, and the mean serum albumin concentration was 3.86±0.47 g/ dl. Mean follow-up time was 35.4±38.4 months. Of the patients, 41.3% received HD treatment with an unmodified cellulose dialyzer, 14.3% with a modified cellulose dialyzer and 44.3% with a synthetic dialyzer. Patients with and without diabetes mellitus had no significant difference in mean cytokine values. Table 2 shows the mean cytokine values for the cohort and a control group of 28 general medical patients without ESRD, as previously reported [12] . Median cytokine values are reported for the ESRD patients because of the skewed distributions. All mean cytokine values were significantly higher in ESRD patients. All the cytokines were intercorrelated, although some of the correlation coefficients were negative [12] . 
Results

Factor analysis
The results of the exploratory factor analysis for the individual cytokine values showed that 63.1% of the variance can be explained by a single factor as opposed to two individual factors. In the rotated factor pattern analysis, there was a trend toward IL-1, IL-2, IL-6 and TNF-α loading onto factor 1, while IL-4, IL-5 and IL-12 loaded onto a second factor. Similar results were found when a logarithmic transformation was performed on the cytokine values.
Frequency analysis
A frequency analysis of cytokine patterns was conducted on the haemodialysis cohort. 65 patients had a pattern of high IL-1, IL-6 and TNF-α levels. These patients had low anti-inflammatory parameters, including IL-2, IL-4, IL-5, IL-12, CH50 and T-cell number. The next most frequent pattern was found in 20 patients with high levels of antiinflammatory parameters (IL-2, IL-4, IL-5, IL-12, CH50 and T-cell number). There were no other common frequency patterns of cytokines in the rest of the cohort. The next most frequent cytokine pattern occurred in only five patients. Table 3 summarizes the baseline medical and demographic characteristics of the three groups in the cohort. Of note, there was no significant difference in hematocrit, albumin and dialysis severity coefficient values between the pro-inflammatory and anti-inflammatory groups. Table  4 shows the mean cytokine values in the pro-inflammatory group (n= 65), anti-inflammatory group (n = 20) and all other patients (n=146). These results show that the patients in the high pro-inflammatory pattern group had significantly higher levels of pro-inflammatory cytokines compared to the anti-inflammatory and other patient groups. It also showed that the 20 patients with a particular pattern of anti-inflammatory cytokines had significantly higher levels of T-cell regulatory parameters.
Using the frequency pattern analysis, we performed a survival analysis (Tables 5 and 6 ) on the 65 patients with a pattern of high pro-inflammatory cytokines compared to the other patient groups. The high pro-inflammatory cytokine pattern group (n=65) had significantly increased mortality compared to the anti-inflammatory cytokine pattern (Figure 1 ). Cox regression analysis showed that the high proinflammatory cytokine pattern group (n=65) had an adjusted hazard ratio for mortality of 2.26 (95% CI 1.445-3.539, P=0.0004) compared to the reference group of all other patients (n=146). The high anti-inflammatory pattern group (n=20) had an adjusted hazard ratio for mortality of 0.603 (95% CI 0.239-1.519, P=0.28) compared to all other patients (n=146).
Discussion
The data showing that the cytokines load predominantly onto one factor are consistent with previous research supporting the 'redundant' and 'pleotropic' role cytokines play in the immune system [20, 21] . Therefore, when 'inflammatory' cytokines are stimulated, it is likely that 'anti-inflammatory' cytokines are increased at the same time in a negative feedback biologic mechanism in order to keep the immune system in regulation in ESRD dialysis patients. The results of correlation analyses showing strong intercorrelations between all the variables also supports this explanation. Interleukins can promote or negate the production of other cytokines and can also have similar actions in different cellular systems [20, 21] .
Our data also show that a group of patients with a specific pattern of high pro-inflammatory cytokines (IL-1, IL-6 and TNF-α) had increased mortality when compared to patients with a pattern of high T-cell regulatory or antiinflammatory parameters (IL-2, IL-4, IL-5, IL-12, CH50 and T-cell number) (Figure 1 ). We and others have previously shown that high levels of individual pro-inflammatory cytokines in ESRD patients were associated with decreased survival or worse outcomes [6, 12, 17, 18, 22, 23] . The reason for the increased mortality among patients with a panel of high pro-inflammatory cytokines may be related to increased risk for cardiovascular mortality [20, 24, 25] . Inflammation in dialysis patients may lead to endothelial damage promoting atherosclerosis and therefore cardiovascular mortality. Inflammation is also a frequent result of chronic longstanding infectious processes. There are multiple sources of inflammation in ESRD patients including infections, exposure to dialysis membranes, hyperparathyroidism, activation of the sympathetic nervous system, hyperlipidaemia and diabetes [6, 24, 25] .
Previous studies have shown that increased levels of individual cytokines are associated with increased mortality in ESRD patients. Tripepi et al. showed that ESRD patients with high levels of C-reactive protein and IL-6 had increased cardiovascular mortality [6] . Rao et al. also showed that high IL-6 levels were associated with decreased survival in haemodialysis patients [17] . Chiang et al. showed that ESRD patients with higher levels of IL-18 had increased hospitalization rates [18] . Bologa et al. showed that higher levels of IL-6 were associated with decreased serum albumin, hypercholesterolaemia and increased mortality [26] .
Our frequency analysis revealed 65 of 231 patients (or 28.1%) with a particular pattern of high pro-inflammatory cytokines. The next most frequent pattern was 20 patients (less than 10%) with a pattern of high anti-inflammatory cytokines and low pro-inflammatory cytokines. The results of our frequency and survival analyses suggest that extreme values of immune system dysregulation are associated with differential survival, and perhaps patterns of cytokines are more useful than the assessment of individual cytokines in predicting mortality outcomes.
This exploratory factor study is limited by its crosssectional nature. Causality cannot be inferred from these data. In addition, this study was performed exclusively in ESRD patients treated with haemodialysis, who may have particularly unique and abnormal immune regulation. For example, there were skewed distributions of the cytokine values in this cohort of patients. This limits the generalizability of our findings to other populations. Unfortunately, we do not have data on cause-specific mortality in this population, but it is likely that the majority of deaths were related to cardiovascular disease. In addition, in order to more completely study the balance of pro-inflammatory and anti-inflammatory cytokines, it would be desirable to study IL-1β, IL-1 receptor antagonist and soluble IL-2 receptor levels simultaneously. Unfortunately, these parameters were not assessed in our studies. Additional studies should focus on novel immunomodulatory therapies that can be designed to control the inflammatory cascade and possibly to incorporate these therapies into renal replacement procedures in the future. Whether an association between the so-called pro-inflammatory and anti-inflammatory cytokines in the circulation of ESRD patients is present, the data suggest that they are linked responses in individual patients and that they may plausibly be considered as one factor, consistent with the concept of a pleotropic and redundant immune system. For ESRD patients treated with HD with either high pro-inflammatory or anti-inflammatory cytokine profiles, a dysregulation of immune function can be inferred, which may have salutary or deleterious consequences. Larger numbers of patients and assessments of pro-inflammatory and anti-inflammatory parameters may be needed to enhance the utility of such studies.
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